<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="bef4d22d-6e29-46ed-bb04-55b1b18e7f20"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Diclofenac Sodium</content>
   </title>
   <effectiveTime value="20250314"/>
   <setId root="e947653c-6789-4c15-82c9-4b1402f6d6ac"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
            <name>Preferred Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                  <name>Preferred Pharmaceuticals Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                        <name>Preferred Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68788-8952" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e6701236-fbfa-4021-a24c-d7b387f7a4aa"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250314"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68788-8952" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Diclofenac Sodium<suffix>Delayed Release</suffix>
                        </name>
                        <formCode code="C42905" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, DELAYED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Diclofenac Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="61442-102" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="QTG126297Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DICLOFENAC SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="144O8QL0L1" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DICLOFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HAF0412YIT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 2000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8952-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20151120"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8952-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20151120"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8952-9" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20151120"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8952-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20151120"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="120"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8952-8" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20151120"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA075185" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20151120"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>Round</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">CTI;102</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="22ebb003-ecf4-4a8b-8ce2-af9499c3985e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Delayed-Release Tablets USP             <br/>Rx only             <br/>Prescribing information          </paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="dfdc0f29-4f37-4106-a250-276ba47c6494"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS </title>
               <text/>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="s3">
                     <id root="a04756c3-4843-46de-8ed2-217e4851980b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Cardiovascular Thrombotic Events</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see                      </content>
                              <content styleCode="bold">).                  </content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Diclofenac sodium delayed-release tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see                      <linkHtml href="#s21">CONTRAINDICATIONS</linkHtml>,                      </content>
                              <content styleCode="bold">).                  </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="7a5ca8e8-fd4b-4024-a741-bbcdc0e8e42a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Gastrointestinal Bleeding, Ulceration, And Perforation</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (see                      </content>
                              <content styleCode="bold">).                  </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="3c81aa1b-c91f-4bf7-90ea-5dc7f76b094d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Diclofenac sodium delayed-release tablets is a benzene-acetic acid derivative. Diclofenac sodium is a white or slightly yellowish crystalline powder and is sparingly soluble in water at 25°C. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C    <sub>14</sub>H    <sub>10</sub>Cl    <sub>2</sub>NNaO    <sub>2</sub>, and it has the following structural formula  </paragraph>
                  <renderMultiMedia ID="id737" referencedObject="mm01"/>
                  <paragraph>The inactive ingredients in diclofenac sodium delayed-release tablets include: hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, sodium starch glycolate, talc, titanium dioxide, triethyl citrate and ink fine black.</paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Figure
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dic05-0006-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="137a0b41-1174-42a8-b5dd-91dda5ef8eb2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="s7">
                     <id root="ec2fbabc-0761-4c34-b361-73bfe20a8bcc"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>Mechanism of Action </title>
                     <text>
                        <paragraph>Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. </paragraph>
                        <paragraph>The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). </paragraph>
                        <paragraph>Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="bfc97e60-34d4-497a-a224-c537c61359c8"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics </title>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="s9">
                           <id root="bc8f0779-2436-444b-ac47-ca7fb41bc9ee"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Absorption </content>
                           </title>
                           <text>
                              <paragraph>Diclofenac is 100% absorbed after oral administration compared to IV administration as measured by urine recovery. However, due to first-pass metabolism, only about 50% of the absorbed dose is systemically available (see                  <linkHtml href="#_Reft1">Table 1</linkHtml>). Food has no significant effect on the extent of diclofenac absorption. However, there is usually a delay in the onset of absorption of 1 to 4.5 hours and a reduction in peak plasma levels of &lt;20%.               </paragraph>
                              <table ID="_Reft1" width="100%">
                                 <caption>Table 1. Pharmacokinetic Parameters for Diclofenac </caption>
                                 <col width="40%"/>
                                 <col width="37%"/>
                                 <col width="21%"/>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" colspan="2" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Normal Healthy Adults (20-48 years)</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <br/>
                                             <content styleCode="bold">Mean</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Coefficient of Mean Variation (%)</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Absolute                          <br/>Bioavailability (%)                          <br/>[N = 7]                        </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>55 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>40 </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>T                          <sub>max</sub> (hr) [N = 56]                        </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>2.3 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>69 </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Oral Clearance (CL/F;                          <br/>mL/min) [N = 56]                        </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>582 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>23 </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Renal Clearance                          <br/>(% unchanged drug in                          <br/>urine) [N = 7]                        </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>&lt;1 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>— </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Apparent Volume of                          <br/>Distribution (V/F; L/kg)                          <br/>[N = 56]                        </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>1.4 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>58 </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Terminal Half-life (hr)                          <br/>[N = 56]                        </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>2.3 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>48 </paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s10">
                           <id root="49278653-d561-445c-abf3-bb5a71265b80"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Distribution </content>
                           </title>
                           <text>
                              <paragraph>The apparent volume of distribution (V/F) of diclofenac sodium is 1.4 L/kg. </paragraph>
                              <paragraph>Diclofenac is more than 99% bound to human serum proteins, primarily to albumin. Serum protein binding is constant over the concentration range (0.15-105 mcg/ml) achieved with recommended doses. </paragraph>
                              <paragraph>Diclofenac diffuses into and out of the synovial fluid. Diffusion into the joint occurs when plasma levels are higher than those in the synovial fluid, after which the process reverses and synovial fluid levels are higher than plasma levels. It is not known whether diffusion into the joint plays a role in the effectiveness of diclofenac. </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s11">
                           <id root="2809b3f8-29ef-428a-9f78-3d1efa25a840"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Elimination </content>
                           </title>
                           <effectiveTime value="20250314"/>
                           <component>
                              <section ID="s12">
                                 <id root="d5f1c936-c5ab-42e0-bc01-672a85e7bc1f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Metabolism </content>
                                 </title>
                                 <text>
                                    <paragraph>Five diclofenac metabolites have been identified in human plasma and urine. The metabolites include 4'-hydroxy-, 5-hydroxy-, 3'-hydroxy-, 4',5-dihydroxy- and 3'-hydroxy-4'-methoxy-diclofenac. The major diclofenac metabolite, 4'-hydroxy-diclofenac, has very weak pharmacologic activity. The formation of 4'-hydroxy- diclofenac is primarily mediated by CYP2C9. </paragraph>
                                    <paragraph>Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuronidation mediated by UGT2B7 and oxidation mediated by CYP2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3'-hydroxy-diclofenac. In patients with renal dysfunction, peak concentrations of metabolites 4'-hydroxy- and 5-hydroxydiclofenac were approximately 50% and 4% of the parent compound after single oral dosing compared to 27% and 1% in normal healthy subjects. </paragraph>
                                 </text>
                                 <effectiveTime value="20250314"/>
                              </section>
                           </component>
                           <component>
                              <section ID="e12">
                                 <id root="8be54a91-af8c-44d0-bcc9-59ad67cfa852"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Excretion </content>
                                 </title>
                                 <text>
                                    <paragraph>Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Because renal elimination is not a significant pathway of elimination for unchanged diclofenac, dosing adjustment in patients with mild to moderate renal dysfunction is not necessary. The terminal half-life of unchanged diclofenac is approximately 2 hours. </paragraph>
                                 </text>
                                 <effectiveTime value="20250314"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="b54206d2-6c0e-42d5-9d56-f8cc93c21044"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Special Populations </title>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="s14">
                           <id root="62403b94-26ec-4cad-8608-08a0d5935c05"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Pediatric:</content> The pharmacokinetics of diclofenac has not been investigated in pediatric patients.               </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="e15">
                           <id root="7509b0c9-bcbe-4911-9e5a-70ac46a2e99d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Race:</content> Pharmacokinetic differences due to race have not been identified.               </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s15">
                           <id root="d33ec9ed-44b0-4e08-ac0d-19a4d17d2611"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Hepatic Impairment:</content> Hepatic metabolism accounts for almost 100% of diclofenac elimination, so patients with hepatic disease may require reduced doses of diclofenac compared to patients with normal hepatic function.               </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s16">
                           <id root="d9c4e37a-e698-44e1-a70a-cf859f140735"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Renal Impairment:</content> Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60-90, 30-60, and &lt;30 mL/min; N=6 in each group), AUC values and elimination rate were comparable to those in healthy subjects.               </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s17">
                           <id root="e66a822e-a2e7-4593-a25b-b0316952329c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Drug Interactions Studies </content>
                           </title>
                           <effectiveTime value="20250314"/>
                           <component>
                              <section ID="s18">
                                 <id root="c69ef6cf-1ffb-4400-9d20-2af7b1ea22f8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Voriconazole:</content> When co-administered with voriconazole (inhibitor of CYP2C9, 2C19 and 3A4 enzyme), the C                   <sub>max</sub> and AUC of diclofenac increased by 114% and 78%, respectively (                   <content styleCode="italics">see                       <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>
                                       </content>).                 </paragraph>
                                 </text>
                                 <effectiveTime value="20250314"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s19">
                                 <id root="f8165b0f-6e54-4a27-b42a-9dee54b6d541"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin:</content> When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. The clinical significance of this interaction is not known. See                    <linkHtml href="#_Reft2">Table 2</linkHtml> for clinically significant drug interactions of NSAIDs with aspirin (                   <content styleCode="italics">see                       <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>
                                       </content>).                 </paragraph>
                                 </text>
                                 <effectiveTime value="20250314"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="bc145433-d302-4fc9-857a-935fda0dc867"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (             <content styleCode="italics">see                 </content>).           </paragraph>
                  <paragraph>Diclofenac is indicated: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>For relief of the signs and symptoms of osteoarthritis </item>
                     <item>
                        <caption>•</caption>For relief of the signs and symptoms of rheumatoid arthritis </item>
                     <item>
                        <caption>•</caption>For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis </item>
                  </list>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="df45c80a-8604-4cf0-b8c2-59c10ecc5804"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Diclofenac sodium delayed-release tablets are contraindicated in the following patients: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (                <content styleCode="italics">see                    </content>,                    ).              </item>
                     <item>
                        <caption>•</caption>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (                <content styleCode="italics">see                    </content>,                    ).              </item>
                     <item>
                        <caption>•</caption>In the setting of coronary artery bypass graft (CABG) surgery (                <content styleCode="italics">see                    </content>).              </item>
                  </list>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">
               <id root="10cc66e0-9b22-43f9-bdd2-5770d22e0070"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="id_link_1f0b81d5-89ca-6f95-e063-6394a90aadec">
                     <id root="c40185f3-fa6f-4150-8a60-722651784f57"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cardiovascular Thromboic Events</title>
                     <text>
                        <paragraph>Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three   <br/> years duration have shown an increased risk of serious cardiovascular (CV)   <br/> thrombotic events, including myocardial infarction (MI), and stroke, which can   <br/> be fatal. Based on available data, it is unclear that the risk for CV thrombotic   <br/> events is similar for all NSAIDs. The relative increase in serious CV thrombotic   <br/> events over baseline conferred by NSAID use appears to be similar in those with   <br/> and without known CV disease or risk factors for CVdisease. However, patients   <br/> with known CV disease or risk factors had a higher absolute incidence of excess   <br/> serious CV thrombotic events, due to their increased baseline rate. Some   <br/> observational studies found that this increased risk of serious CV thrombotic   <br/> events began as early as the first weeks of treatment. The increase in CV   <br/> thrombotic risk has been observed most consistently at higher doses.  </paragraph>
                        <paragraph>To minimize the potential risk for an adverse CV event in NSAID-treated patients,   <br/> use the lowest effective dose for the shortest duration possible. Physicians and   <br/> patients should remain alert for the development of such events, throughout the   <br/> entire treatment course, even in the absence of previous CV symptoms. Patients   <br/> should be informed about the symptoms of serious CV events and the  </paragraph>
                        <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the   <br/> increased risk of serious CV thrombotic events associated with NSAID use. The   <br/> concurrent use of aspirin and an NSAID, such as diclofenac, increases the risk   <br/> of serious gastrointestinal (GI) events (see    <linkHtml href="#id_link_1f0c3215-5e2c-bad4-e063-6294a90a39d4">WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation</linkHtml>).  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="id_link_1f0bd7e9-c105-c6a9-e063-6294a90a8eea">
                           <id root="97fff99a-eb06-432b-93c1-af3277d9a6a6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Status Post Coronary Artery Bypass Graft (CABG) Surgery</content>
                           </title>
                           <text>
                              <paragraph>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment   <br/> of pain in the first 10 -14 days following CABG surgery found an increased   <br/> incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the   <br/> setting of CABG (see    <linkHtml href="#s21">CONTRAINDICATIONS</linkHtml>).  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_1f0be6f8-9fb0-fafb-e063-6294a90a2f30">
                           <id root="3b74ea36-06a6-4112-9ff3-b2df1bbc9e29"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Post-MI Patients</content>
                           </title>
                           <text>
                              <paragraph>Observational studies conducted in the Danish National Registry have   <br/> demonstrated that patients treated with NSAIDs in the post-MI period were   <br/> at increased risk of reinfarction, CV-related death, and all-cause mortality   <br/> beginning in the first week of treatment. In this same cohort, the incidence of   <br/> death in the first year post-MI was 20 per 100 person years in NSAIDtreated   <br/> patients compared to 12 per 100 person years in non-NSAID exposed patients.   <br/> Although the absolute rate of death declined somewhat after the first year post-   <br/> MI, the increased relative risk of death in NSAID users persisted over at least   <br/> the next four years of follow-up. Avoid the use of diclofenac sodium delayedrelease   <br/> tablets in patients with a recent MI unless the benefits are expected   <br/> to outweigh the risk of recurrent CV thrombotic events. If diclofenac sodium   <br/> delayed-release tablets are used in patients with a recent MI, monitor patients   <br/> for signs of cardiac ischemia.  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c3215-5e2c-bad4-e063-6294a90a39d4">
                     <id root="6b7d6d76-a112-4133-8a55-17c261fdf42f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Gastrointestinal Bleeding, Ulceration, and Perforation</title>
                     <text>
                        <paragraph>NSAIDs, including diclofenac, cause serious gastrointestinal (GI) adverse events   <br/> including inflammation, bleeding, ulceration, and perforation of the esophagus,   <br/> stomach, small intestine, or large intestine, which can be fatal. These serious   <br/> adverse events can occur at any time, with or without warning symptoms, in   <br/> patients treated with NSAIDs. Only one in five patients, who develop a serious upper   <br/> GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding,   <br/> or perforation caused by NSAIDs occurred in approximately 1% of patients treated   <br/> for 3-6 months, and in about 2%-4% of patients treated for one year. However, even   <br/> short-term therapy is not without risk.  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="id_link_1f0c3bc2-a201-759f-e063-6294a90a9d87">
                           <id root="1b151be3-5390-478e-b78a-55a309f9e9de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Risk Factors for GI Bleeding, Ulceration, and Perforation</content>
                           </title>
                           <text>
                              <paragraph>Patients with a prior history of peptic ulcer disease and/or GI bleeding who use   <br/> NSAIDs had a greater than 10-fold increased risk for developing a GI bleed   <br/> compared to patients without these risk factors. Other factors that increase the   <br/> risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID   <br/> therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective   <br/> serotonin reuptake inhibitors (SSRIs):, smoking, use of alcohol, older age, and poor   <br/> general health status. Most postmarketing reports of fatal GI events occurred in   <br/> elderly or debilitated patients. Additionally, patients with advanced liver disease   <br/> and/or coagulopathy are at increased risk for GI bleeding.  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_1f0c3bc2-a203-759f-e063-6294a90a9d87">
                           <id root="cd0aa29d-1901-4615-b1af-aaa7472043f5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Strategies to Minimize the GI Risks in NSAID-treated patients</content>
                           </title>
                           <text>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Use the lowest effective dosage for the shortest possible duration.</item>
                                 <item>
                                    <caption>•</caption>Avoid administration of more than one NSAID at a time</item>
                                 <item>
                                    <caption>•</caption>Avoid use in patients at higher risk unless benefits are expected to outweigh</item>
                              </list>
                              <paragraph>the increased risk of bleeding. For such patients, as well as those with active GI   <br/> bleeding, consider alternate therapies other than NSAIDs.  </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID</item>
                              </list>
                              <paragraph>therapy.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>If a serious GI adverse event is suspected, promptly initiate evaluation and</item>
                              </list>
                              <paragraph>treatment, and discontinue diclofenac sodium delayed-release tablets until a   <br/> serious GI adverse event is ruled out.  </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis,</item>
                              </list>
                              <paragraph>monitor patients more closely for evidence of GI bleeding (see    <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>).  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c3215-5e2e-bad4-e063-6294a90a39d4">
                     <id root="f671a533-3d67-45c5-bde7-32f7001d2f92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hepatotoxicity</title>
                     <text>
                        <paragraph>In clinical trials of diclofenac- containing products,meaningful elevations (i.e.,more   <br/> than 3 times the ULN) of AST (SGOT) were observed in about 2% of approximately   <br/> 5,700 patients at some time during diclofenac treatment (ALT was not measured   <br/> in all studies).  </paragraph>
                        <paragraph>
                           <br/> In a large, open-label, controlled trial of 3,700 patients treated with oral diclofenac   <br/> sodium for 2-6 months, patients were monitored first at 8 weeks and 1,200 patients   <br/> were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST   <br/> occurred in about 4% of patients and included marked elevations (greater than 8   <br/> times the ULN) in about 1% of the 3,700 patients. In that open-label study, a higher   <br/> incidence of borderline (less than 3 times the ULN), moderate (3-8 times the ULN),   <br/> and marked (greater than 8 times the ULN) elevations of ALT or AST was observed   <br/> in patients receiving diclofenac when compared to other NSAIDs. Elevations in   <br/> transaminases were seen more frequently in patients with osteoarthritis than in   <br/> those with rheumatoid arthritis.  </paragraph>
                        <paragraph>
                           <br/> Almost all meaningful elevations in transaminases were detected before patients   <br/> became symptomatic. Abnormal tests occurred during the first 2 months of   <br/> therapy with diclofenac in 42 of the 51 patients in all trials who developed marked   <br/> transaminase elevations.  </paragraph>
                        <paragraph>
                           <br/> In postmarketing reports, cases of drug-induced hepatotoxicity have been reported   <br/> in the first month, and in some cases, the first 2 months of therapy, but can occur at   <br/> any time during treatment with diclofenac. Postmarketing surveillance has reported   <br/> cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant   <br/> hepatitis with and without jaundice, and liver failure. Some of these reported cases   <br/> resulted in fatalities or liver transplantation.  </paragraph>
                        <paragraph>In a European retrospective population-based, case-controlled study, 10 cases of   <br/> diclofenac associated drug-induced liver injury with current use compared with   <br/> non-use of diclofenac were associated with a statistically significant 4-fold adjusted   <br/> odds ratio of liver injury. In this particular study, based on an overall number of 10   <br/> cases of liver injury associated with diclofenac, the adjusted odds ratio increased   <br/> further with female gender, doses of 150 mg or more, and duration of use for more   <br/> than 90 days.  </paragraph>
                        <paragraph>
                           <br/> Physicians should measure transaminases at baseline and periodically in patients   <br/> receiving long-term therapy with diclofenac, because severe hepatotoxicity may   <br/> develop without a prodrome of distinguishing symptoms. The optimum times for   <br/> making the first and subsequent transaminase measurements are not known.   <br/> Based on clinical trial data and postmarketing experiences, transaminases should   <br/> be monitored within 4 to 8 weeks after initiating treatment with diclofenac. However,   <br/> severe hepatic reactions can occur at any time during treatment with diclofenac.  </paragraph>
                        <paragraph>
                           <br/> If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent   <br/> with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia,   <br/> rash, abdominal pain, diarrhea, dark urine, etc.), diclofenac should be discontinued   <br/> immediately.  </paragraph>
                        <paragraph>
                           <br/> Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea,   <br/> fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness,   <br/> and “flu-like” symptoms). If clinical signs and symptoms consistent with liver   <br/> disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.),   <br/> discontinue diclofenac immediately, and perform a clinical evaluation of the patient.  </paragraph>
                        <paragraph>
                           <br/> To minimize the potential risk for an adverse liver related event in patients treated   <br/> with diclofenac, use the lowest effective dose for the shortest duration possible.   <br/> Exercise caution when prescribing diclofenac with concomitant drugs that are   <br/> known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics).  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c634b-ce5c-8646-e063-6394a90ab3c1">
                     <id root="2f57956e-1c3a-4ffc-bc5b-5a70f761e526"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hypertension</title>
                     <text>
                        <paragraph>NSAIDs, including diclofenac, can lead to new onset of hypertension or worsening of   <br/> preexisting hypertension, either of which may contribute to the increased incidence   <br/> of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors,   <br/> thiazides diuretics, or loop diuretics may have impaired response to these therapies   <br/> when taking NSAIDs. (see    <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>).  </paragraph>
                        <paragraph>
                           <br/> Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout   <br/> the course of therapy.  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c653b-3c94-dfb3-e063-6394a90a70eb">
                     <id root="2703ad9f-ea1e-43ac-82d5-cf35faa1e18e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Heart Failure and Edema</title>
                     <text>
                        <paragraph>The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized   <br/> controlled trials demonstrated an approximately two-fold increase in hospitalizations   <br/> for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated   <br/> patients compared to placebo-treated patients. In a Danish National Registry study   <br/> of patients with heart failure, NSAID use increased the risk of MI, hospitalization for   <br/> heart failure, and death.  </paragraph>
                        <paragraph>
                           <br/> Additionally, fluid retention and edema have been observed in some patients treated   <br/> with NSAIDs. Use of diclofenac may blunt the CV effects of several therapeutic   <br/> agents used to treat these medical conditions [e.g, diuretics, ACE inhibitors, or   <br/> angiotensin receptor blockers (ARBs)] (see    <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>).   <br/> Avoid the use of diclofenac in patients with severe heart failure unless the benefits   <br/> are expected to outweigh the risk of worsening heart failure. If diclofenac is used  </paragraph>
                        <paragraph>in patients with severe heart failure, monitor patients for signs of worsening heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c3215-5e30-bad4-e063-6294a90a39d4">
                     <id root="dd9d2ffc-d6fb-4445-a0c3-d03dc739c5dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Renal Toxicity and Hyperkalemia</title>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="id_link_1f0c79de-f3b1-f184-e063-6394a90afa6b">
                           <id root="7e987c3a-7994-4c1e-88e7-aad076e00be8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Renal Toxicity</content>
                           </title>
                           <text>
                              <paragraph>Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal   <br/> injury.  </paragraph>
                              <paragraph>Renal toxicity has also been seen in patients in whom renal prostaglandins have a   <br/> compensatory role in the maintenance of renal perfusion. In these patients, administration   <br/> of a NSAID may cause a dose-dependent reduction in prostaglandin formation and,   <br/> secondarily, in renal blood flow, which may precipitate overt renal decompensation.   <br/> Patients at greatest risk of this reaction are those with impaired renal function, dehydration,   <br/> hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or   <br/> ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery   <br/> to the pretreatment state. No information is available from controlled clinical studies   <br/> regarding the use of diclofenac in patients with advanced renal disease. The renal effects   <br/> of diclofenac may hasten the progression of renal dysfunction in patients with pre-existing   <br/> renal disease.  </paragraph>
                              <paragraph>Correct volume status in dehydrated or hypovolemic patients prior to initiating diclofenac.   <br/> Monitor renal function in patients with renal or hepatic impairment,heart failure,dehydration,   <br/> or hypovolemia during use of diclofenac (see    <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>). Avoid the   <br/> use of diclofenac in patients with advanced renal disease unless the benefits are expected   <br/> to outweigh the risk of worsening renal function. If diclofenac is used in patients with   <br/> advanced renal disease, monitor patients for signs of worsening renal function.  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_1f0c7e97-348d-275d-e063-6394a90a30c2">
                           <id root="0cddf4cc-661a-4cfd-888a-365035c3f2ff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Hyperkalmia</content>
                           </title>
                           <text>
                              <paragraph>Increases in serum potassium concentration, including hyperkalemia, have been reported   <br/> with use of NSAIDs, even in some patients without renal impairment. In patients with normal   <br/> renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism   <br/> state.  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c79de-f3b3-f184-e063-6394a90afa6b">
                     <id root="df0677e0-a517-493b-adf5-a740988f284e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Anaphylactic Reactions</title>
                     <text>
                        <paragraph>Diclofenac has been associated with anaphylactic reactions in patients with and without   <br/> known hypersensitivity to diclofenac and in patients with aspirin-sensitive asthma (see   <br/>
                           <linkHtml href="#s21">CONTRAINDICATIONS</linkHtml>,   <linkHtml href="#id_link_1f0c8b27-7cd7-d485-e063-6394a90ad32f">WARNINGS;Exacerbation of Asthma Related to Aspirin Sensitivity</linkHtml>).  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c8b27-7cd7-d485-e063-6394a90ad32f">
                     <id root="d05642aa-db43-4d29-ab1d-2ad69aed88de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Exacerbation of Asthma Related to Aspirin Sensitivity</title>
                     <text>
                        <paragraph>A subpopulation of patients with asthma may have aspirin-sensitive asthma which may   <br/> include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal   <br/> bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because crossreactivity   <br/> between aspirin and other NSAIDs has been reported in such aspirinsensitive patients,   <br/> diclofenac is contraindicated in patients with this form of aspirin sensitivity (see   <br/>
                           <linkHtml href="#s21">CONTRAINDICATIONS</linkHtml>). When diclofenac is used in patients with preexisting asthma   <br/> (without known aspirin sensitivity),monitor patients for changes in the signs and symptoms   <br/> of asthma.  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c902e-3fce-3150-e063-6294a90aeb0c">
                     <id root="85eb62c4-3e0f-4309-88c8-979424127fc6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Serious Skin Reactions</title>
                     <text>
                        <paragraph>NSAIDs, including diclofenac, can cause serious skin adverse reactions such as exfoliative   <br/> dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which   <br/> can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a   <br/> more severe variant known as generalized bullous fixed drug eruption (GBFDE), which   <br/> can be life-threatening. These serious events may occur without warning. Inform patients   <br/> about the signs and symptoms of serious skin reactions, and to discontinue the use   <br/> of diclofenac at the first appearance of skin rash or any other sign of hypersensitivity.   <br/> Diclofenac is contraindicated in patients with previous serious skin reactions to NSAIDs   <br/> (see    <linkHtml href="#s21">CONTRAINDICATIONS</linkHtml>).  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c9878-65b4-459b-e063-6294a90abd3c">
                     <id root="ce7b1036-b03b-4dab-adea-d56db89d55f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</title>
                     <text>
                        <paragraph>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported   <br/> in patients taking NSAIDs such as Diclofenac Sodium. Some of these events have been   <br/> fatal or life-threatening. DRESS typically, although not exclusively, presents with fever,   <br/> reaction, lymphadenopathy, and/or facial swelling. Other clinical anifestations may include   <br/> hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes   <br/> symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present.   <br/> Because this disorder is variable in its presentation, other organ systems not noted here   <br/> may be involved. It is important to note that early manifestations of hypersensitivity, such   <br/> as fever or lymphadenopathy, may be present even though rash is not evident. If such   <br/> signs or symptoms are present, discontinue Diclofenac Sodium and evaluate the patient   <br/> immediately.  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0c9caf-2d9e-0244-e063-6294a90a5612">
                     <id root="1c03ed23-70f3-4299-8e44-6096b1e59b0f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Fetal Toxicity</title>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="id_link_1f0ca21c-d381-f8bf-e063-6294a90a8271">
                           <id root="a0ea97a9-21b6-481b-bb0a-42f46e8b65bb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Premature Closure of Fetal Ductus Arteriosus</content>
                           </title>
                           <text>
                              <paragraph>Avoid use of NSAIDs, including Diclofenac Sodium, in pregnant women at about 30 weeks   <br/> gestation and later. NSAIDs including Diclofenac Sodium, increase the risk of premature   <br/> closure of the fetal ductus arteriosus at approximately this gestational age.  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_1f0ca21c-d383-f8bf-e063-6294a90a8271">
                           <id root="85e047ee-412a-400a-b57a-ebfaae1f254c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Oligohydramnios/Neonatal Renal Impairment</content>
                           </title>
                           <text>
                              <paragraph>Use of NSAIDs, including Diclofenac Sodium, at about 20 weeks gestation or later in   <br/> pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some   <br/> cases, neonatal renal impairment.These adverse outcomes are seen, on average, after days   <br/> to weeks of treatment, although oligohydramnios has been infrequently reported as soon   <br/> as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with   <br/> treatment discontinuation. Complications of prolonged oligohydramnios may, for example,   <br/> include limb contractures and delayed lung maturation. In some postmarketing cases of   <br/> impaired neonatal renal function, invasive procedures such as exchange transfusion or   <br/> dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30   <br/> weeks gestation, limit Diclofenac Sodium use to the lowest effective dose and shortest   <br/> duration possible. Consider ultrasound monitoring of amniotic fluid if Diclofenac Sodium   <br/> treatment extends beyond 48 hours. Discontinue Diclofenac Sodium if oligohydramnios   <br/> occurs and follow up according to clinical practice [see    <linkHtml href="#s59">PRECAUTIONS; Pregnancy</linkHtml>].  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="id_link_1f0cac38-da76-9b25-e063-6394a90a1bca">
                     <id root="b3f8cf0f-cc0b-4ddb-a8f7-c034cabb360f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hematologic Toxicity</title>
                     <text>
                        <paragraph>Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood   <br/> loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient   <br/> treated with diclofenac, has any signs or symptoms of anemia, monitor hemoglobin or   <br/> hematocrit. NSAIDs, including diclofenac, may increase the risk of bleeding events. Comorbid   <br/> conditions such as coagulation disorders, concomitant use of warfarin, other   <br/> anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and   <br/> serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these   <br/> patients for signs of bleeding (see    <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>).  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s39">
               <id root="76b9111d-a83a-4a20-b766-72c8589204b8"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS SECTION</title>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="s40">
                     <id root="6bdba91c-e842-43da-8d49-e94b65bd9b78"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General </title>
                     <text>
                        <paragraph>Diclofenac sodium delayed-release tablets cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids and the patient should be observed closely for any evidence of adverse effects, including adrenal insufficiency and exacerbation of symptoms of arthritis. </paragraph>
                        <paragraph>The pharmacological activity of diclofenac in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s41">
                     <id root="6ca33b3e-a9a5-41b8-9b92-75b32392906e"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients Section</title>
                     <text>
                        <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed. Inform patients, families, or their caregivers of the following information before initiating therapy with diclofenac and periodically during the course of ongoing therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="s42">
                           <id root="c7f4cfac-654d-4b52-86cf-b8c1133bfd64"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Cardiovascular Thrombotic Events</content>
                           </title>
                           <text>
                              <paragraph>Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their healthcare provider immediately    <content styleCode="italics">(see     </content>
                                 <content styleCode="italics">).    </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s43">
                           <id root="cf28b746-9243-4907-b00e-08c192a1561a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                           </title>
                           <text>
                              <paragraph>Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of GI bleeding    <content styleCode="italics">(see     </content>
                                 <content styleCode="italics">).    </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s44">
                           <id root="069ce434-d4bf-44a7-9a97-daaf7b692886"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Hepatotoxicity</content>
                           </title>
                           <text>
                              <paragraph>Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, diarrhea, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, instruct patients to stop diclofenac and seek immediate medical therapy    <content styleCode="italics">(see     </content>
                                 <content styleCode="italics">).    </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s45">
                           <id root="446f9e22-63e2-4b25-a9df-16935b696fe8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Heart Failure and Edema</content>
                           </title>
                           <text>
                              <paragraph>Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur    <content styleCode="italics">(see     </content>
                                 <content styleCode="italics">).    </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s46">
                           <id root="1e224586-8762-424c-9c22-c34ca59c53d3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Anaphylactic Reactions</content>
                           </title>
                           <text>
                              <paragraph>Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur    <content styleCode="italics">(see     </content>
                                 <content styleCode="italics">).    </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s47">
                           <id root="8c9bb184-c0a5-47f3-bf4d-8a71e786e2c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Serious Skin Reactions, including DRESS</content>
                           </title>
                           <text>
                              <paragraph>Advise patients to stop taking diclofenac sodium immediately if they develop any type of rash or fever and to contact their healthcare provider as soon as possible    <content styleCode="italics">(see     </content>
                                 <content styleCode="italics">).    </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s48">
                           <id root="1080eb4f-f297-4354-8a46-e5524180e7db"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Female Fertility </content>
                           </title>
                           <text>
                              <paragraph>Advise females of reproductive potential who desire pregnancy that NSAIDs, including diclofenac, may be associated with a reversible delay in ovulation                  <content styleCode="italics">(see                     <linkHtml href="#s55">PRECAUTIONS; Carcinogenesis, Mutagenesis, Impairment of Fertility</linkHtml>).                 </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s49">
                           <id root="1c668441-0269-4634-87e5-5469d05397c7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Fetal Toxicity</content>
                           </title>
                           <text>
                              <paragraph>Inform pregnant women to avoid use of diclofenac sodium and other NSAIDs, starting at 30 weeks gestation because of the risk of the premature closure of the fetal ductus arteriosus. If treatment with diclofenac sodium is needed for a pregnant woman between about 20 to 30 gestation, advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours [see   <linkHtml href="#id_link_1f0c9caf-2d9e-0244-e063-6294a90a5612">WARNINGS; Fetal Toxicity</linkHtml>;    <linkHtml href="#s59">PRECAUTIONS; Pregnancy</linkHtml>]  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s50">
                           <id root="fc4dfc03-c2d1-4e11-b06f-804d0be32a47"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Avoid Concomitant Use of NSAIDs </content>
                           </title>
                           <text>
                              <paragraph>Inform patients that the concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy                  <content styleCode="italics">(see                     </content>
                                 <content styleCode="italics"> and                     <linkHtml href="#s54">Drug Interactions</linkHtml>).                 </content> Alert patients that NSAIDs may be present in “over the counter” medications for treatment of colds, fever, or insomnia.               </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s51">
                           <id root="7b3ecf93-bc51-44e1-bc5d-48e90fc12f1f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Use of NSAIDS and Low-Dose Aspirin </content>
                           </title>
                           <text>
                              <paragraph>Inform patients not to use low-dose aspirin concomitantly with diclofenac until they talk to their healthcare provider                  <content styleCode="italics">(see                     <linkHtml href="#s54">PRECAUTIONS; Drug Interactions</linkHtml>).                 </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s52">
                     <id root="cba2ea3f-1910-41af-8c6d-476effbc9fd0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Masking of Inflammation and Fever </title>
                     <text>
                        <paragraph>The pharmacological activity of diclofenac in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s53">
                     <id root="bbe21b7f-9c65-4245-aa22-22065414a48d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Laboratory Monitoring </title>
                     <text>
                        <paragraph>Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long term NSAID treatment with a CBC and a chemistry profile periodically                <content styleCode="italics">(see                   </content>, and                   <content styleCode="italics">).               </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="7b3759c0-844e-4c74-bb0c-1759205d5222"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions </title>
                     <text>
                        <paragraph>See                <linkHtml href="#_Reft2">Table 2</linkHtml> for clinically significant drug interactions with diclofenac.             </paragraph>
                        <table ID="_Reft2" width="100%">
                           <caption>Table 2: Clinically Significant Drug Interactions with Diclofenac </caption>
                           <col width="26%"/>
                           <col width="72%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Drugs That Interfere with Hemostasis</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. </item>
                                       <item>
                                          <caption>•</caption>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Monitor patients with concomitant use of diclofenac with anticoagulants (e.g., warfarin), antiplatelet agents                        <br/>(e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (                        <content styleCode="italics">see                            <linkHtml href="#s39">PRECAUTIONS</linkHtml>;                            </content>).                      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Aspirin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone                         <content styleCode="italics">(see</content>
                                       <br/>
                                       <content styleCode="italics">WARNINGS; Gastrointestinal Bleeding, Ulceration, and                            </content>
                                       <content styleCode="italics">)                        </content>.                      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Concomitant use of diclofenac and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (                        <content styleCode="italics">see                            <linkHtml href="#s39">PRECAUTIONS: Hematological Toxicity</linkHtml>
                                       </content>).                        <br/>Diclofenac is not a substitute for low dose aspirin for cardiovascular protection.                      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). </item>
                                       <item>
                                          <caption>•</caption>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>During concomitant use of diclofenac and </item>
                                       <item>
                                          <caption>•</caption>ACE-inhibitors, ARBs, or betablockers, monitor blood pressure to ensure that the desired blood pressure is obtained. </item>
                                       <item>
                                          <caption>•</caption>During concomitant use of diclofenac and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (                              <content styleCode="italics">see                                  </content>).                            </item>
                                       <item>
                                          <caption>•</caption>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Diuretics </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>During concomitant use of diclofenac with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (                        <content styleCode="italics">see                            </content>).                      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Digoxin </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>During concomitant use of diclofenac and digoxin, monitor serum digoxin levels. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Lithium </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>During concomitant use of diclofenac and lithium, monitor patients for signs of lithium toxicity. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Methotrexate </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>During concomitant use of diclofenac and methotrexate, monitor patients for methotrexate toxicity. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cyclosporine </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Concomitant use of diclofenac and cyclosporine may increase cyclosporine's nephrotoxicity. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>During concomitant use of diclofenac and cyclosporine, monitor patients for signs of worsening renal function. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>NSAIDs and Salicylates </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (                        <content styleCode="italics">see                            </content>).                      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pemetrexed </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Concomitant use of diclofenac and pemetrexed may increase the risk of pemetrexedassociated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td align="justify" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>During concomitant use of diclofenac and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.                        <br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.                        <br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.                      </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>CYP2C9 Inhibitors or Inducers: </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (                        <content styleCode="italics">see                            <linkHtml href="#s8">CLINICAL PHARMACOLOGY; Pharmacokinetics</linkHtml>
                                       </content>).                      </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s55">
                     <id root="ba303473-0f62-4844-af2d-934b15a84b3d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="s56">
                           <id root="e7699b09-3707-4ba7-9ff1-a111467d473c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Carcinogenesis </content>
                           </title>
                           <text>
                              <paragraph>Long-term carcinogenicity studies in rats given diclofenac sodium up to 2 mg/kg/day (approximately 0.1 times maximum recommended human dose (MRHD) of diclofenac, 200 mg/day, based on body surface area (BSA) comparison ) have revealed no significant increases in tumor incidence. A 2-year carcinogenicity study conducted in mice employing diclofenac sodium at doses up to 0.3 mg/kg/day (approximately 0.007 times the MRHD based on BSA comparison) in males and 1 mg/kg/day (approximately 0.02 times the MRHD based on BSA comparison) in females did not reveal any oncogenic potential. </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s57">
                           <id root="bdf4b83c-c4b2-45f6-95a1-0394d9fab2a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Mutagenesis </content>
                           </title>
                           <text>
                              <paragraph>Diclofenac sodium did not show mutagenic activity in                  <content styleCode="italics">in vitro</content> point mutation assays in mammalian (mouse lymphoma) and microbial (yeast, Ames) test systems and was nonmutagenic in several mammalian                  <content styleCode="italics">in vitro</content> and                  <content styleCode="italics">in vivo</content> tests, including dominant lethal and male germinal epithelial chromosomal studies in mice, and nucleus anomaly and chromosomal aberration studies in Chinese hamsters.               </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s58">
                           <id root="33cc6bda-2b0f-465e-ba17-4cf6380c5d4b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Impairment of Fertility </content>
                           </title>
                           <text>
                              <paragraph>Diclofenac sodium administered to male and female rats at 4 mg/kg/day (approximately 0.2 times the MRHD based on BSA comparison) did not affect fertility. </paragraph>
                              <paragraph>Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including diclofenac, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including diclofenac, in women who have difficulties conceiving or who are undergoing investigation of infertility. </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s59">
                     <id root="a39b1359-0972-4bfb-ba14-4d09f61b81c2"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy Section</title>
                     <effectiveTime value="20250314"/>
                     <component>
                        <section ID="s60">
                           <id root="094eb5c0-faaa-4d5d-a4c0-ebccc1759762"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>Use of NSAIDs, including diclofenac, can cause premature closure of the fetal ductus arteriosusand fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of Diclofenac Sodium use between about 20 and 30 weeks of gestation, and avoid Diclofenac Sodium use at about 30 weeks of gestation and later in pregnancy.</paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="italics">Premature Closure of Fetal Ductus Arteriosus</content>
                                 <br/> Use of NSAIDs, including Diclofenac Sodium, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus.  </paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="italics">Oligohydramnios/Neonatal Renal Impairment</content>
                                 <br/> Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment.  </paragraph>
                              <paragraph>
                                 <br/> Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In animal reproduction studies, no evidence of teratogenicity was observed in mice, rats or rabbits given diclofenac during the period of organogenesis at doses up to approximately 0.5 and 1 times, respectively, the maximum recommended human dose (MRHD) of diclofenac sodium delayedrelease, 200mg/day, despite the presence of maternal and fetal toxicity at these doses (see    ).  </paragraph>
                              <paragraph>
                                 <br/> The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. [see    <linkHtml href="#id_link_1f0c9caf-2d9e-0244-e063-6294a90a5612">WARNINGS; Fetal Toxicity</linkHtml>].  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_1f1b12d3-2e4d-f0ec-e063-6294a90a065c">
                           <id root="c4014e13-030c-41a3-b011-e3124f30678e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                 <br/> Premature Closure of Fetal Ductus Arteriosus:   <br/> Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, including Diclofenac Sodium, can cause premature closure of the fetal ductus arteriosus (see    <linkHtml href="#id_link_1f0c9caf-2d9e-0244-e063-6294a90a5612">WARNINGS; Fetal Toxicity</linkHtml>).   <br/>
                                 <content styleCode="italics">Oligohydramnios/Neonatal Renal Impairment</content>
                                 <br/> If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible. If Diclofenac Sodium treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. If oligohydramnios occurs, discontinue Diclofenac Sodium and follow up according to clinical practice (see    <linkHtml href="#id_link_1f0c9caf-2d9e-0244-e063-6294a90a5612">WARNINGS; Fetal Toxicity</linkHtml>).  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_1f1b15cb-584f-1234-e063-6294a90a6518">
                           <id root="584d5ae2-0ca1-4aa7-84e1-1a5ce0143ddf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Data: Human Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Premature Closure of Fetal Ductus Arteriosus:</content>
                                 <br/>
                                 <content styleCode="italics">Oligohydramnios/Neonatal Renal Impairment:</content>
                                 <br/> Published studies and postmarketing reports describe maternal NSAID use at about 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. In many cases, but not all, the decrease in amniotic fluid was transient and reversible with cessation of the drug.There have been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. Some cases of neonatal renal dysfunction required treatment with invasive procedures, such as exchange transfusion or dialysis.   <br/> Methodological limitations of these postmarketing studies and reports include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications. These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAID use. Because the published safety data on neonatal outcomes involved mostly preterm infants, the generalizability of certain reported risks to the full-term infant exposed to NSAIDs through maternal use is uncertain.  </paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s62">
                           <id root="1f7e661c-51ac-47b5-bad5-fcf84c545869"/>
                           <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                           <title>
                              <content styleCode="bold">Data: Animal Data</content>
                           </title>
                           <text>
                              <paragraph>Reproductive and developmental studies in animals demonstrated that diclofenac sodium administration during organogenesis did not produce teratogenicity despite the induction of maternal toxicity and fetal toxicity in mice at oral doses up to 20 mg/kg/day (approximately 0.5 times the maximum recommended human dose [MRHD] of diclofenac, 200 mg/day, based on body surface area (BSA) comparison), and in rats and rabbits at oral doses up to 10 mg/kg/day (approximately 0.5 and 1 times, respectively, the MRHD based on BSA comparison). In a study in which pregnant rats were orally administered 2 or 4 mg/kg diclofenac (0.1 and 0.2 times the MRHD based on BSA) from Gestation Day 15 through Lactation Day 21, significant maternal toxicity (peritonitis, mortality) was noted. These maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival. Diclofenac has been shown to cross the placental barrier in mice, rats, and humans.</paragraph>
                           </text>
                           <effectiveTime value="20250314"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s63">
                     <id root="c365df19-214b-4823-b043-ae58bd4abb9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Labor or Delivery </title>
                     <text>
                        <paragraph>There are no studies on the effects of diclofenac during labor or delivery. In animal studies, NSAIDS, including diclofenac, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s64">
                     <id root="fad46bc5-dff0-4c45-a4f2-0c8208da5a50"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Risk Summary</content>
                           </content>
                           <br/> Based on available data, diclofenac may be present in human milk.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for diclofenac and any potential adverse effects on the breastfed infant from the diclofenac or from the underlying maternal condition.  </paragraph>
                        <paragraph>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="underline">Data</content>
                           </content>
                           <br/> One woman treated orally with a diclofenac salt, 150 mg/day, had a milk diclofenac level of 100 mcg/L, equivalent to an infant dose of about 0.03 mg/kg/ day. Diclofenac was not detectable in breast milk in 12 women using diclofenac (after either 100 mg/day orally for 7 days or a single 50 mg intramuscular dose administered in the immediate postpartum period).  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s67">
                     <id root="ce851f45-bfab-4e4d-b820-900f6d44b73d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="s68">
                     <id root="40c0f610-b74e-419a-bb03-c696045031d6"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use </title>
                     <text>
                        <paragraph>Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects                <content styleCode="italics">(see                   </content>,                   ,                   ,                   <content styleCode="italics">,                   <linkHtml href="#s53">PRECAUTIONS; Laboratory Monitoring</linkHtml> )               </content>.             </paragraph>
                        <paragraph>Diclofenac is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function                <content styleCode="italics">(See                   <linkHtml href="#s6">CLINICAL PHARMACOLOGY</linkHtml>,                   </content>
                           <content styleCode="italics">).               </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_1f0cc5e8-a563-1f84-e063-6394a90a1202">
               <id root="6c6624f3-e86c-49d7-87ab-23193b5710e7"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS SECTION</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Cardiovascular Thrombotic Events (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>GI Bleeding, Ulceration and Perforation (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Hepatotoxicity (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Hypertension (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Heart Failure and Edema (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Renal Toxicity and Hyperkalemia (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Anaphylactic Reactions (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Serious Skin Reactions (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                     <item>
                        <caption>•</caption>Hematologic Toxicity (see     <linkHtml href="#id_link_1f0b08f6-7934-f2bf-e063-6294a90a6b67">WARNINGS</linkHtml>)   </item>
                  </list>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="id_link_1f0ce586-782f-6cc2-e063-6294a90a1e46">
                     <id root="9b6e1dcb-9008-4bd8-b729-542f1167280d"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed</paragraph>
                        <paragraph>in practice.</paragraph>
                        <paragraph>In patients taking diclofenac sodium delayed-release tablets, or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1%-10% of patients are:</paragraph>
                        <paragraph>Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting.   <br/> Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes and tinnitus.  </paragraph>
                        <paragraph>Additional adverse experiences reported occasionally include:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Body as a Whole: fever, infection, sepsis</content>
                           <br/>
                           <content styleCode="bold">Cardiovascular System</content>: congestive heart failure, hypertension, tachycardia, syncope   <br/>
                           <content styleCode="bold">Digestive System:</content> dry mouth, esophagitis, gastric/peptic ulcers, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatitis, jaundice   <br/>
                           <content styleCode="bold">Hemic and Lymphatic System</content>: ecchymosis, eosinophilia, leukopenia, melena, purpura, rectal bleeding, stomatitis, thrombocytopenia   <br/>
                           <content styleCode="bold">Metabolic and Nutritional</content>: weight changes   <br/>
                           <content styleCode="bold">Nervous System</content>: anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia,malaise, nervousness, paresthesia, somnolence, tremors, vertigo   <br/>
                           <content styleCode="bold">Respiratory System</content>: asthma, dyspnea   <br/>
                           <content styleCode="bold">Skin and Appendages</content>: alopecia, photosensitivity, sweating increased   <br/>
                           <content styleCode="bold">Special Senses</content>: blurred vision   <br/>
                           <content styleCode="bold">Urogenital System</content>: cystitis, dysuria, hematuria, interstitial nephritis, oliguria/ polyuria, proteinuria, renal failure  </paragraph>
                        <paragraph>Other adverse reactions, which occur rarely are:   <br/>
                           <content styleCode="bold">Body as a Whole:</content> anaphylactic reactions, appetite changes, death   <br/>
                           <content styleCode="bold">Cardiovascular System</content>: arrhythmia, hypotension, myocardial infarction, palpitations, vasculitis   <br/>
                           <content styleCode="bold">Digestive System</content>: colitis, eructation, fulminant hepatitis with and without jaundice, liver failure, liver necrosis, pancreatitis   <br/>
                           <content styleCode="bold">Hemic and Lymphatic System</content>: agranulocytosis, hemolytic anemia, aplastic anemia, lymphadenopathy, pancytopenia   <br/>
                           <content styleCode="bold">Metabolic and Nutritional:</content> hyperglycemia   <br/>
                           <content styleCode="bold">Nervous System</content>: convulsions, coma, hallucinations, meningitis   <br/>
                           <content styleCode="bold">Respiratory System</content>: respiratory depression, pneumonia   <br/>
                           <content styleCode="bold">Skin and appendages</content>: Angioedema, toxic epidermal necrosis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, fixed drug eruption (FDE), urticaria   <br/>
                           <content styleCode="bold">Special Senses</content>: conjunctivitis, hearing impairment  </paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s71">
               <id root="f8e4ed02-82f6-4924-a8a1-4dbc20e3caec"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE </title>
               <text>
                  <paragraph>Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression and coma have occurred, but were rare.              <content styleCode="italics">(see                 <linkHtml href="#s42">WARNINGS; Cardiovascular Thrombotic Events</linkHtml>,                 </content>,                 ,                 <content styleCode="italics">) .             </content>
                  </paragraph>
                  <paragraph>Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within  four hours of ingestion or in patients with a large overdose (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding. </paragraph>
                  <paragraph>For additional information about overdosage treatment contact a poison control center (1-800-222-1222). </paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="s72">
               <id root="b6514af9-5c39-4fe0-bfa6-e0c564d99ff2"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals              <content styleCode="italics">(see                 </content>
                     <content styleCode="italics">)             </content>.           </paragraph>
                  <paragraph>After observing the response to initial therapy with diclofenac, the dose and frequency should be adjusted to suit an individual patient's needs. </paragraph>
                  <paragraph>For the relief of osteoarthritis, the recommended dosage is 100-150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day). </paragraph>
                  <paragraph>For the relief of rheumatoid arthritis, the recommended dosage is 150-200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day.). </paragraph>
                  <paragraph>For the relief of ankylosing spondylitis, the recommended dosage is 100-125 mg/day, administered as 25 mg four times a day, with an extra 25-mg dose at bedtime if necessary. </paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="id_link_1c31e712-5c38-8733-e063-6394a90ab9ab">
               <id root="9e96aa38-af93-46e3-a230-dc7b1ccdf503"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Diclofenac sodium delayed-release tablets</content>
                  </paragraph>
                  <paragraph>50 mg – white to off-white, biconvex, round-shaped, unscored (imprinted    <renderMultiMedia ID="id1989" referencedObject="img_1c31e4c3-f72c-83ad-e063-6394a90ad222"/> on one side), supplied in bottles of:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>Bottles of 30	NDC 68788-8952-3</item>
                     <item>
                        <caption> </caption>Bottles of 60	NDC 68788-8952-6</item>
                     <item>
                        <caption> </caption>Bottles of 90	NDC 68788-8952-9</item>
                     <item>
                        <caption> </caption>Bottles of 100	NDC 68788-8952-1</item>
                     <item>
                        <caption> </caption>Bottles of 120	NDC 68788-8952-8</item>
                  </list>
                  <paragraph>Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Protect from moisture.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Dispense in tight container (USP).</content>
                  </paragraph>
                  <paragraph>Manufactured and Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Carlsbad Technology, Inc.</content>
                  </paragraph>
                  <paragraph>5923 Balfour Court   <br/> Carlsbad, CA 92008 USA  </paragraph>
                  <paragraph>Revised: 07/2024   <br/> CTI-11 Rev. L  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Repackaged By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="img_1c31e4c3-f72c-83ad-e063-6394a90ad222">
                     <text>dic05-0006-03</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dic05-0006-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s75">
               <id root="f9ce8db9-f88f-45ce-9775-bbd2c94413b6"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="s77">
               <id root="c32e7595-6376-4c61-a957-5a18ed9f089e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>Principal Display Panel – Bottle Label</paragraph>
                  <paragraph>NDC 68788-8952</paragraph>
                  <paragraph>Diclofenac Sodium</paragraph>
                  <paragraph>Delayed-Release Tablets USP</paragraph>
                  <paragraph>50 mg</paragraph>
                  <paragraph>PHARMACIST: PLEASE DISPENSE WITH MEDICATION GUIDE</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Carlsbad Technology, Inc.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Repackaged By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
                  <renderMultiMedia ID="id2233" referencedObject="mm06"/>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="mm06">
                     <text>Diclofenac Sodium Delayed-Release Tablets 50mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dic05-0006-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>